Sun Pharma - FDA seizure to affect US sales

On the back of the FDA's product seizures at Sun's US subsidiary, Caraco on June
25th, Analysts across the street have lowered revenue and earnings estimates by 8-10% across FY2010E-2012E to reflect the impact on Sun's US sales. As a consequence of declining earnings (19% decline in FY10 vs. FY09) and lowered returns in FY10, Goldman's Returns-based TP is reduced by 18% to Rs947 and we downgrade the stock to a Sell with a potential downside of 17%.